MWA
CRSP icon

Moser Wealth Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Moser Wealth Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$4.86K Sell
100
-250
-71% -$9.68K ﹤0.01% 163
2025
Q1 		$11.9K Hold
350
– – 0.01% 125
2024
Q4 		$13.8K Hold
350
– – 0.01% 110
2024
Q3 		$16.4K Buy
350
+50
+17% +$2.54K 0.01% 110
2024
Q2 		$16.2K Buy
300
+100
+50% +$5.78K 0.01% 112
2024
Q1 		$13.6K Hold
200
– – 0.01% 115
2023
Q4 		$12.5K Hold
200
– – 0.01% 112
2023
Q3 		$9.08K Hold
200
– – 0.01% 110
2023
Q2 		$11.2K Buy
+200
New +$11.3K 0.01% 107
2022
Q4 		$8.13K Buy
200
+150
+300% +$7.96K 0.01% 105
2022
Q3 		$3K Hold
50
– – ﹤0.01% 126
2022
Q2 		$3K Hold
50
– – ﹤0.01% 122
2022
Q1 		$3K Hold
50
– – ﹤0.01% 125
2021
Q4 		$4K Hold
50
– – ﹤0.01% 128
2021
Q3 		$6K Buy
+50
New +$6.28K ﹤0.01% 122

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Moser Wealth Advisors's CRSP Position: Q2 2025 in Review

Moser Wealth Advisors reduced its CRISPR Therapeutics (CRSP) stake by 71% in Q2 2025, selling an estimated $9.68K and leaving 100 shares worth $4.86K. The position accounts for ﹤0.01% of the portfolio, ranked #163.

Moser Wealth Advisors first reported a position in CRSP in Q3 2021 and has held it in 15 quarters since. The position peaked at $16.4K in Q3 2024. 433 funds tracked by Wall St. Rank hold CRSP as of Q2 2025.

  • Moser Wealth Advisors held 100 shares of CRISPR Therapeutics worth $4.86K as of Q2 2025.
  • Moser Wealth Advisors sold 250 CRISPR Therapeutics shares in Q2 2025, an estimated $9.68K.
  • CRISPR Therapeutics made up ﹤0.01% of Moser Wealth Advisors's portfolio in Q2 2025, its #163 holding.
  • Moser Wealth Advisors first reported a position in CRISPR Therapeutics in Q3 2021 and has held it in 15 quarters since.
  • Moser Wealth Advisors's CRISPR Therapeutics position peaked at $16.4K in Q3 2024.
  • 433 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2025.

Based on Moser Wealth Advisors's 13F filing for Q2 2025, filed 31 Jul 2025.